Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

11 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MkXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXy3NkBp NVvQXGFoTE2VTx?= NF3SfodKSzVyPUCuNFAxODdizszN NFXaU5YyPzl3NkC4NC=>
K562 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\ldJpmPzJiaB?= NYewPIpiTE2VTx?= MXrJR|UxRTBwMECxJO69VQ>? NX3JSm9bOTd7NU[wPFA>
M07e M4XJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnNb2Y5PzJiaB?= MoOySG1UVw>? NE\wWGFKSzVyPUCuNFAyOiEQvF2= MUixO|k2PjB6MB?=
ALL3 M1myWmN6fG:2b4jpZ{BCe3OjeR?= MYqwMlHPxE1? NWjLNXQ4PzJiaB?= NH7qcFlFVVOR M1rhTmlEPTB;MD6wNFA1KM7:TR?= NVzleGt[OTl6OEm1OFA>
CML MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUH5fmtXOjBibXnu MnzuSG1UVw>? MWLJR|UxRTBwMECxJO69VQ>? NEfwTHcyQTJzOUCxOi=>
BA/F3 Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\HO|IhcA>? MWPEUXNQ NFfhUlhKSzVyPU[uOVg6KM7:TR?= MXKyN|A5QDZ2NB?=
BA/F3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nSbFczKGh? NHvKSIRFVVOR Mlq1TY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDNN|UyXCCvdYThcpQhf2m2aDDJR|UxKG:oIECuNFAxQDQQvF2= MYSyN|A5QDZ2NB?=
BA/F3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWK3NkBp M1\6XGROW09? NG\IemtKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP MYqyN|A5QDZ2NB?=
BA/F3 NV;F[I4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPkSo84OiCq NX7YXJdpTE2VTx?= NYLOWXlEUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN NXLTNY81OjNyOEi2OFQ>
BA/F3 NUG0XVRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTDV5o4OiCq NEP6WYxFVVOR NWjUdIZGUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2= MXqyN|MxOTdyMx?=
BA/F3 MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX73cIFTPzJiaB?= NH;oWZVFVVOR M4XUcGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP NFfPS4kzOzNyMUewNy=>
BA/F3 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi0N|E4OiCq MmDESG1UVw>? MmO4TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1? NUXEeogyOjN|MEG3NFM>
BA/F3 M3vxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoSwO|IhcA>? NH;RSY1FVVOR NEXofVZKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCTMkWyTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA5|ryP MXOyN|MxOTdyMx?=
BA/F3 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L0Z|czKGh? MWrEUXNQ NVy3VIVlUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUO1PXYhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOTQQvF2= NUTNNlh5OjN|MEG3NFM>
BA/F3 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK3NkBp NEPQNYVFVVOR NIDxcHNKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>? NYrGW3N7OjN|MEG3NFM>
BA/F3 M{e0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\uNIp4PzJiaB?= NVLUbVFITE2VTx?= MY\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? NH3kRoQzOzNyMUewNy=>
BA/F3 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX1ZVF1PzJiaB?= M3PDcWROW09? MnmzTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0> M3TrPFI{OzBzN{Cz
BA/F3 M2TjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13YW|czKGh? MoXjSG1UVw>? MWTJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCyMlXPxE1? NVrsc5dOOjN|MEG3NFM>
T cell MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3RdIduPzJiaB?= MULEUXNQ NITz[ZdKdmirYnn0d{BidnSrIFPEN{0h[W6mIHHueIkhS0R{OD3pcoR2[2WmIGSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwN:69VQ>? M3TaRVE4OTV2NUGy
WiDr MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Plc|czKGh? M3PUVmROW09? M3y2dmlEPTB;MD6wOVIh|ryP MWWxOVYyPTVzMh?=
PC3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmyUIY4OiCq NGfwO5lFVVOR NYXDbXoxUUN3ME2wMlAxQTRizszN NELrVY0yPTZzNUWxNi=>
MDA-MB-231 M3ixNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:3NkBp NVr6TYI5TE2VTx?= NFnIUIxKSzVyPUCuNFEzKM7:TR?= NGjnU2wyPTZzNUWxNi=>
Hs578T MoTiR5l1d3SxeHnjJGF{e2G7 NXqwUXBIPzJiaB?= MYjEUXNQ NXTtV3BIT0l3ME2wMlA{KM7:TR?= M2LYbVI1ODF3M{K3
HMEC NF\MdGdEgXSxdH;4bYMhSXO|YYm= M1LzVlczKGh? NEjwZXlFVVOR NFfhN|VIUTVyPUGuPEDPxE1? MVyyOFAyPTN{Nx?=
DU145 NVjpfZQ2S3m2b4TvfIlkKEG|c3H5 M{LoUlczKGh? MlzYSG1UVw>? NHW3NlFIUTVyPUCuNVYh|ryP NGHud2MzPDBzNUOyOy=>
U251 M3q3TmN6fG:2b4jpZ{BCe3OjeR?= MV23NkBp M2L0eGROW09? MnXTS2k2OD1{LkixJO69VQ>? MUGyOFAyPTN{Nx?=
NCI60 NILvU5dEgXSxdH;4bYMhSXO|YYm= NHfzWI44OiCq NV;yeow3TE2VTx?= MYjHTVUxRTVwNzFOwG0> MmDSNlQxOTV|Mke=
MALME-3M Moe5R5l1d3SxeHnjJGF{e2G7 NUnFTXJCPzJiaB?= NGrGXFJFVVOR NUjUbHpDT0l3ME22MlYyKM7:TR?= NImwUHAzPDBzNUOyOy=>
KM12 MkH2R5l1d3SxeHnjJGF{e2G7 M4TZNlczKGh? NI\mfINFVVOR NWLFNFltT0l3ME23MlQ1KM7:TR?= MkHxNlQxOTV|Mke=
SW620 Mk\ER5l1d3SxeHnjJGF{e2G7 NV3vTlNwPzJiaB?= NGfSN4FFVVOR NVzmeJZWT0l3ME24MlQ{KM7:TR?= MkW2NlQxOTV|Mke=
RXF 393NL Mon6R5l1d3SxeHnjJGF{e2G7 M2TrdlQh\GG7cx?= MXnEUXNQ MnrqTWM2OD1yLkCyNVch|ryP NV\jT2R3OjN{NUOwO|Q>
LXFA 983L NWDD[3BxS3m2b4TvfIlkKEG|c3H5 M4\sVFQh\GG7cx?= MlTZSG1UVw>? NYfG[phuUUN3ME2wMlA2PjVizszN NVjhXHByOjN{NUOwO|Q>
PRXF DU145 NGHrWoZEgXSxdH;4bYMhSXO|YYm= NFfYRnc1KGSjeYO= NFPqT2pFVVOR M2nMTmlEPTB;MD6wOlI{KM7:TR?= MmG5NlMzPTNyN{S=
PAXF 1657L MnvHR5l1d3SxeHnjJGF{e2G7 M3nGOVQh\GG7cx?= MVvEUXNQ NYXl[VRZUUN3ME2wMlEzOSEQvF2= NEL3TWEzOzJ3M{C3OC=>
CXF 1103L MnrTR5l1d3SxeHnjJGF{e2G7 NH65bo81KGSjeYO= M3flNGROW09? NGGxVHNKSzVyPUSuN|Yh|ryP M3K4VFI{OjV|MEe0
GXF251L NYG0cW9NS3m2b4TvfIlkKEG|c3H5 NVrTZWFDPCCmYYnz NHPKW3NFVVOR MX7JR|UxRTJwMkWg{txO NWSzbGw4OjN{NUOwO|Q>
NCI-H23 MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;iO|IhcA>? M4j0cGROW09? MlrwTWM2OD1{LkK3JO69VQ>? NXnJR4tNOjN3MkGwNlA>
HCT116 NUfSUFBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojIO|IhcA>? NIC0fHZFVVOR M3nuO2lEPTB;Mj6zJO69VQ>? NHPofmkzOzV{MUCyNC=>
MCF7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu3NkBp M33u[WROW09? NXz1[lB{UUN3ME2yMlU4KM7:TR?= M2TYXVI{PTJzMEKw
NCI-H460 MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYri[oFwPzJiaB?= NYHkfmJMTE2VTx?= M3T0[WlEPTB;OD65PUDPxE1? MoH2NlM2OjFyMkC=
DLD1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknqO|IhcA>? M2izcWROW09? MoDwTWM2OD12Lk[g{txO MYGyN|U3Pzl4MB?=
NCI-H661 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fM[|czKGh? NYrQN3ZuTE2VTx?= NF7VNYVKSzVyPUeuPEDPxE1? M3nhe|I{PTZ5OU[w
A549 NYLEZWNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKzTHI4OiCq NFvyenhFVVOR M1L2eGlEPTB;OD6yJO69VQ>? MY[yN|U3Pzl4MB?=
U937 NF;GZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TCU|czKGh? MlXiSG1UVw>? M4HmTWlEPTB;MUKuNkDPxE1? NEHzXpgzOzV4N{m2NC=>
HEK293 M1zJfWZ2dmO2aX;uJGF{e2G7 M3jQc|ExyqEQvF2= MY\EUXNQ NIjqNnFKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm|LYTh[4dm\CCPeYSxJItqdmG|ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB4M988US=> MmHrNlI4PzB4MUC=
HUVEC M3\PN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3zNE4yPcLizszN NUD3NHJkPzJiaB?= NVPhN2JwTE2VTx?= MoHLTY5lfWOnczDhcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGSyClbz3jeYx1fXKnZDD3bZRpKH[jc3P1cIFzKHOvb3;0bEBufXOlbHWgZ4VtdHNiYYPz[ZN{\WRiYYOgTY5pcWKrdHnvckBw\iClZXzsJIdzd3e2aDDheEAxNjF3IIXN NHy4[|QzOjh3M{m5Ny=>
HUVEC MXfGeY5kfGmxbjDBd5NigQ>? NXvZV|NlOTYEoN88US=> MkTqO|IhcA>? NXnlOFlXTE2VTx?= NWTERYhCUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? MkH6NlI5PTN7OUO=
Plasmodium falciparum NEfwU|BHfW6ldHnvckBCe3OjeR?= NEjaeo4yOMLizszN M4K2PFE2KG2rbh?= NWXYSYRlTE2VTx?= NWHXd49JUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4|ryP NYWzOmUyOjR3NUCzN|A>
PC3 NX\1[mwxTnWwY4Tpc44hSXO|YYm= M{P4clAvOSEQvF2= NYPkPYRKPSCq NVPDboR[TE2VTx?= M4[1NWlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= M3nE[VE6PDZ{OUe1
DU145 M{XPfWZ2dmO2aX;uJGF{e2G7 MXKwMlEh|ryP M3[4b|UhcA>? MXvEUXNQ Ml63TY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= NUTvWHR3OTl2NkK5O|U>
PC3 M{XadGtqdmG|ZTDBd5NigQ>? NVXsdGp5OC5zIN88US=> MYi1JIg> M1\TTGROW09? NIHoUVJKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N NULkXHp6OTl2NkK5O|U>
DU145 MVnLbY5ie2ViQYPzZZk> M17kUVAvOSEQvF2= NY\mXFBzPSCq MXzEUXNQ MVTJcohq[mm2czDjV5JkKGmwIHj1cYFvKESXMUS1JINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBw\iCyaH;zdIhwenmuYYTl[EBUemNiWUSxOkBt\X[nbDDheEAyODBibl2= MkjRNVk1PjJ7N{W=
PC3 NEjKfIhMcW6jc3WgRZN{[Xl? M1foZVAvOSEQvF2= NIm5UpU2KGh? MlrySG1UVw>? MlP3TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O NHTlfVIyQTR4Mkm3OS=>
DU145 NXHa[WxKU2mwYYPlJGF{e2G7 M4H2cVAvOSEQvF2= M{P5eFUhcA>? M3nmfmROW09? NXXCVVh1UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= NHfWR5kyQTR4Mkm3OS=>
Huh7 MVzBcpRqfmm{YXygRZN{[Xl? MW[yMlUh|ryP MXm0JIRigXN? MmW5SG1UVw>? NYjlW5ZvUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN M4q0ZlE4OzZyNke2
C6/36 MlvrRY51cX[rcnHsJGF{e2G7 MXKyMlUh|ryP MVq0JIRigXN? Mk\mSG1UVw>? M2TGUGlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? M{P3UFE4OzZyNke2
U937 M3radmZ2dmO2aX;uJGF{e2G7 MUOxJO69VQ>? MoH6NUBp Mn3WSG1UVw>? NXTWOWhrWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= MUWxO|Y5PDB7OR?=
U937 M{\oVWZ2dmO2aX;uJGF{e2G7 MXKxJO69VQ>? NXO3bmRtOSCq MXTEUXNQ M4O0fHJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{ MYGxO|Y5PDB7OR?=
murine mast cell MUnGeY5kfGmxbjDBd5NigQ>? NV;pcXV5OSEQvF2= MYCyOEBp MnHvSG1UVw>? MoHnTY5pcWKrdIOgZY51cWenbj3pcoR2[2WmIFnMOkB{\WO{ZYTpc44hcW5iSXfFJJBzcW2nZDDtc5V{\SCvYYP0JINmdGy|IHH0JFEhfU1? NWHSTFRCOTd4OESwPVk>
BV-173 NV7tcIpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwMECwNFAxOTB7IN88US=> MlnBV2FPT0WU
K-562 M3v2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn65TWM2OD1yLkCwNFAxODJ4NjFOwG0> MYjTRW5ITVJ?
BL-70 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S0T2lEPTB;MD6wNFAxODB6MkKg{txO M{nI[nNCVkeHUh?=
EM-2 NVr6VmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjCV|VKSzVyPUCuNFAxODBzMEig{txO M1ryT3NCVkeHUh?=
LAMA-84 Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvUR4RKSzVyPUCuNFAxODB|MkGg{txO NYPuZY1lW0GQR1XS
MEG-01 M1nwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37XemlEPTB;MD6wNFAxODl6IN88US=> NUe0OFlNW0GQR1XS
EoL-1-cell MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfWTWM2OD1yLkCwNFAyOzFizszN NV;RNYdYW0GQR1XS
CTV-1 M3vIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG0TWM2OD1yLkCwNFA1ODRizszN MYrTRW5ITVJ?
TE-15 Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMEC1PFkh|ryP NYDidoZPW0GQR1XS
NOS-1 M3m0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\BemlEPTB;MD6wNFYyOyEQvF2= MVnTRW5ITVJ?
D-336MG NVLWNFVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\rTWM2OD1yLkCwOlMh|ryP MW\TRW5ITVJ?
LB1047-RCC MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2xTWM2OD1yLkCwPVg6KM7:TR?= MmH6V2FPT0WU
LB996-RCC NEnYVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTkTWM2OD1yLkCwPVkyKM7:TR?= M{TXUHNCVkeHUh?=
SW982 M4Tme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnmT5FWUUN3ME2wMlAyOTF3IN88US=> M13BTHNCVkeHUh?=
TK10 MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvsdZFKSzVyPUCuNFEyPzRizszN M3jsfnNCVkeHUh?=
A704 NETuRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEG0PVEh|ryP M2ftbnNCVkeHUh?=
TE-8 NIjteHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[3WnVTUUN3ME2wMlAyPTd4IN88US=> NWXjcYgxW0GQR1XS
DOHH-2 M2SxZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq1TWM2OD1yLkCxO|E6KM7:TR?= NV\Z[JJZW0GQR1XS
HOP-62 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PRN2lEPTB;MD6wNVg{PCEQvF2= NWjjTo03W0GQR1XS
TE-12 MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSxWoFKSzVyPUCuNFE5PjFizszN MlHaV2FPT0WU
KGN NFm4UWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K4PGlEPTB;MD6wNVk1OiEQvF2= MUHTRW5ITVJ?
NCI-H1648 NVrT[YtlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjFXWhTUUN3ME2wMlAzODFzIN88US=> Mkn1V2FPT0WU
OS-RC-2 M4Dzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3qzTmlEPTB;MD6wNlA{KM7:TR?= NWq0d25[W0GQR1XS
GB-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMEKxOVch|ryP NWPnSGxCW0GQR1XS
RXF393 NFLqO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTBbo1KSzVyPUCuNFI{PTdizszN MmXuV2FPT0WU
LC-2-ad MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPBTWM2OD1yLkCyOVg3KM7:TR?= NE\TW21USU6JRWK=
KS-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYThNZRxUUN3ME2wMlAzPzNizszN MkPtV2FPT0WU
ETK-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3xTodNUUN3ME2wMlAzQDN{IN88US=> M3;tO3NCVkeHUh?=
SW954 NXjJfGlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\QfGlEPTB;MD6wNlkzPyEQvF2= NGi5NXJUSU6JRWK=
Becker MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nuZ2lEPTB;MD6wN|AxOyEQvF2= MnPKV2FPT0WU
MZ1-PC NWfa[3VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXjZYxQUUN3ME2wMlA{OTF7IN88US=> M{H5WnNCVkeHUh?=
ES6 NES0S|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn1[YhWUUN3ME2wMlA{OTl|IN88US=> NWrMWGJ2W0GQR1XS
KURAMOCHI NFzWVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fHcmlEPTB;MD6wN|Q5PyEQvF2= NFuze3hUSU6JRWK=
CGTH-W-1 NWP1NVNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonOTWM2OD1yLkCzOVQ5KM7:TR?= Mn:zV2FPT0WU
VA-ES-BJ M3e1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPRdpRKSzVyPUCuNFM6ODJizszN NEnVdHRUSU6JRWK=
LXF-289 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmmzTWM2OD1yLkCzPVU3KM7:TR?= MmnUV2FPT0WU
MPP-89 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTnTWM2OD1yLkC0NFQ6KM7:TR?= MnvaV2FPT0WU
SW872 NXXReGZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHtTWM2OD1yLkC0NVYyKM7:TR?= NInNWndUSU6JRWK=
SNB75 NVTzXWRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHWTWM2OD1yLkC0OFM2KM7:TR?= MUfTRW5ITVJ?
PSN1 NVmxdGI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn4WItKSzVyPUCuNFQ1PzRizszN M2XUN3NCVkeHUh?=
LB831-BLC M{PvV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMES2NFkh|ryP NHKzV2lUSU6JRWK=
MFH-ino NYnvUZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;DdWtKSzVyPUCuNFQ4OjRizszN MkHEV2FPT0WU
TGBC24TKB NXm0d5hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3iS2piUUN3ME2wMlA1PzZzIN88US=> NHr2e3VUSU6JRWK=
A388 NYfyVmRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DrdmlEPTB;MD6wOVA6PSEQvF2= MlWzV2FPT0WU
BB30-HNC MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT6TpdKUUN3ME2wMlA2PDN5IN88US=> NFiwd2VUSU6JRWK=
GI-ME-N NG\KPWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHLWnBKSzVyPUCuNFYyOThizszN NU\Yd|lzW0GQR1XS
TGBC1TKB MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnDTWM2OD1yLkC2NVY1KM7:TR?= MnrFV2FPT0WU
TE-10 M3n1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TNS2lEPTB;MD6wOlM2PyEQvF2= NXfOTolsW0GQR1XS
A498 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jnTWlEPTB;MD6wO|I5PCEQvF2= NY\EXZd6W0GQR1XS
TE-11 M363Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGW4fZFKSzVyPUCuNFc5PThizszN M{\1SnNCVkeHUh?=
BB65-RCC M3frZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DnN2lEPTB;MD6wPFIzPyEQvF2= MXTTRW5ITVJ?
C2BBe1 M1HzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEizNFgh|ryP MVXTRW5ITVJ?
NCI-H747 NUDUOZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwMEizOlIh|ryP NHzvZolUSU6JRWK=
IST-MES1 MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMEi1OVIh|ryP MVXTRW5ITVJ?
KALS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki2TWM2OD1yLkC5OFkh|ryP MYjTRW5ITVJ?
GCIY NIPqXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG4dGxKSzVyPUCuNFk3PTZizszN M2P2O3NCVkeHUh?=
RL95-2 NEeycVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrHTWM2OD1yLkGwN|gh|ryP M2\G[nNCVkeHUh?=
TE-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDvPG1nUUN3ME2wMlExPTRizszN NVfPNWNMW0GQR1XS
NCI-H1355 M{XTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT5[pJjUUN3ME2wMlEyODJ6IN88US=> Mo\SV2FPT0WU
SW962 NGXhdJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPIe5pkUUN3ME2wMlEyOjl{IN88US=> NWnoO5dQW0GQR1XS
KLE Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj5SpFwUUN3ME2wMlEyOzF5IN88US=> NYnS[4E4W0GQR1XS
MC116 NWDNd5F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXCTWM2OD1yLkGxOFEh|ryP MnTHV2FPT0WU
NMC-G1 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXzOIFKSzVyPUCuNVE3ODZizszN NHGzNphUSU6JRWK=
KU812 NYi3e45lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjiTWM2OD1yLkGxPFg{KM7:TR?= Mln0V2FPT0WU
COLO-829 M3PUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TTOGlEPTB;MD6xNlIyOyEQvF2= MUPTRW5ITVJ?
NTERA-S-cl-D1 Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMUKyPFMh|ryP M4fVT3NCVkeHUh?=
IST-MEL1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33hW2lEPTB;MD6xN|Q2KM7:TR?= NUf5eZFvW0GQR1XS
MLMA NGHSVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYqzPZE5UUN3ME2wMlE1ODN{IN88US=> MnjZV2FPT0WU
LS-123 NEjmcoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK1fmNLUUN3ME2wMlE1ODZ2IN88US=> NXP5bZF3W0GQR1XS
LB2518-MEL MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDSZ3BKSzVyPUCuNVQyPjJizszN M1\lU3NCVkeHUh?=
NB69 NYDZeGc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMUS0N|Yh|ryP MWnTRW5ITVJ?
8-MG-BA MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\yTWM2OD1yLkG1OFU5KM7:TR?= NYP1XGhSW0GQR1XS
K5 M1fxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTmTWM2OD1yLkG2OFg6KM7:TR?= MkjQV2FPT0WU
KINGS-1 NX;1WHdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\0dmV5UUN3ME2wMlE3PjZ4IN88US=> NEXWTmVUSU6JRWK=
SF268 NWfsWWNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DZNWlEPTB;MD6xO|QxPCEQvF2= MWXTRW5ITVJ?
PF-382 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\xTWM2OD1yLkG3Olc5KM7:TR?= MlfDV2FPT0WU
SH-4 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDlTWM2OD1yLkG4OFE{KM7:TR?= Mkm5V2FPT0WU
NALM-6 NWr4eG9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDHd5ZLUUN3ME2wMlE6Ojl3IN88US=> NGDGfo9USU6JRWK=
CP66-MEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jMcWlEPTB;MD6xPVU{OSEQvF2= M2X1dnNCVkeHUh?=
697 MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMUm5PFch|ryP M3G3RXNCVkeHUh?=
CP67-MEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMkC0PFgh|ryP NH;yN|RUSU6JRWK=
DSH1 Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\iTWM2OD1yLkK0NFAyKM7:TR?= NF;YdXdUSU6JRWK=
HCE-4 M4LLTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\WWlFKSzVyPUCuNlY1OzlizszN MnvvV2FPT0WU
MZ2-MEL NEfLPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnPcnNKSzVyPUCuNlg2OzdizszN MWHTRW5ITVJ?
BL-41 NFvWNWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnxNHJiUUN3ME2wMlI6OTJ|IN88US=> MYPTRW5ITVJ?
HUTU-80 NV7rWWFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D0b2lEPTB;MD6zNVQzKM7:TR?= Mn3qV2FPT0WU
LOXIMVI MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzVTWM2OD1yLkOxOVA{KM7:TR?= MVXTRW5ITVJ?
no-10 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDTZ2wxUUN3ME2wMlMyQTNzIN88US=> M4rFTnNCVkeHUh?=
KARPAS-422 NGryZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\adnRXUUN3ME2wMlM{QTl5IN88US=> MXfTRW5ITVJ?
SW684 M4PxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTBwM{S5PEDPxE1? MlPtV2FPT0WU
SF126 NVX6d5NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TIOmlEPTB;MD6zOVQyKM7:TR?= MmX6V2FPT0WU
D-263MG MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwM{[yNlQh|ryP M4\YOnNCVkeHUh?=
OVCAR-4 M4S1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jOcGlEPTB;MD6zO|Q{OyEQvF2= NH36OI5USU6JRWK=
BB49-HNC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHJTWM2OD1yLkO4OVk6KM7:TR?= MlmzV2FPT0WU
ONS-76 NWm3UJd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XLeGlEPTB;MD60Nlk2OSEQvF2= M2C2bXNCVkeHUh?=
MZ7-mel M1;sUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i5N2lEPTB;MD60O|kyOSEQvF2= MV3TRW5ITVJ?
RCC10RGB MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjsTlJPUUN3ME2wMlQ6OTFizszN NXr0[5ZPW0GQR1XS
BOKU MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfYTWM2OD1yLkS5NVM{KM7:TR?= MVrTRW5ITVJ?
no-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGxTWM2OD1yLkWwNlI5KM7:TR?= MX3TRW5ITVJ?
IST-SL2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLmbmE5UUN3ME2wMlUxOzB{IN88US=> NWT6S4ZzW0GQR1XS
RKO NIiySmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vNdWlEPTB;MD61Nlk3PiEQvF2= NULDeGxvW0GQR1XS
HT-144 NFXFZ|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDtV453UUN3ME2wMlU{PjB7IN88US=> M{LqbnNCVkeHUh?=
NCI-H446 NWL4cGp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwNkK3OkDPxE1? MVzTRW5ITVJ?
QIMR-WIL NEGyR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HyfWlEPTB;MD63NFYzQSEQvF2= MmHDV2FPT0WU
MHH-PREB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwN{S0Olkh|ryP M1XacHNCVkeHUh?=
EW-16 NITVfGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjQVIVKSzVyPUCuO|YyPzhizszN Ml72V2FPT0WU
EW-24 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHwTWM2OD1yLke4NVY2KM7:TR?= MY\TRW5ITVJ?
LB373-MEL-D NXX1fphsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwOEK1NFgh|ryP Ml3pV2FPT0WU
TE-9 NIC3WWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwOEe1N|Ih|ryP MXHTRW5ITVJ?
A3-KAW MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTBwOUi0OVIh|ryP NImzdJBUSU6JRWK=
A101D MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[wVmlEPTB;MT6wN|A1OyEQvF2= NWDOelNHW0GQR1XS
OCUB-M MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu2TWM2OD1zLkC0OFEzKM7:TR?= MnnhV2FPT0WU
ES4 M3;4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPDcpRKSzVyPUGuNFUyPDVizszN NWW0TGRTW0GQR1XS
TE-6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFwMkGyNlYh|ryP MV\TRW5ITVJ?
D-502MG M4HFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjBSY14UUN3ME2xMlI{Ozd4IN88US=> MmfzV2FPT0WU
KNS-42 NGTBc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnqeJJKSzVyPUGuNlQ1OTJizszN MUTTRW5ITVJ?
SNU-C2B NV7TPVNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{W1V2lEPTB;MT6zNFU5QSEQvF2= NVvPUIxOW0GQR1XS
NCI-H1838 NF;Kd5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPZTWM2OD1zLkOwO|M{KM7:TR?= NITmcJRUSU6JRWK=
NKM-1 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTFwM{C4OVkh|ryP M{\GXXNCVkeHUh?=
GI-1 NEXLNHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\yOmlEPTB;MT6zOlIzKM7:TR?= M2HQRXNCVkeHUh?=
NB5 M4H6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jLWWlEPTB;MT6zPVgzPyEQvF2= NWLFbpVxW0GQR1XS
CAS-1 NGXMfJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwNEC5PVIh|ryP NULlV4F6W0GQR1XS
HCE-T MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K3VWlEPTB;MT61OlcyPCEQvF2= MYTTRW5ITVJ?
SBC-1 NXz6b4wzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnGTWM2OD1zLkW3PVg1KM7:TR?= MknOV2FPT0WU
JiyoyeP-2003 NH3FSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LHc2lEPTB;MT63N|Q3PiEQvF2= M33jZ3NCVkeHUh?=
TE-5 NY\uN4t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TmdmlEPTB;MT63PVE{QSEQvF2= NWjHXm0{W0GQR1XS
CAN NEj0boJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu4XGYxUUN3ME2xMlgzOjV{IN88US=> NEm2RnBUSU6JRWK=
SK-UT-1 MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXWbmV[UUN3ME2yMlE3Pjl|IN88US=> NEXmOIJUSU6JRWK=
JVM-2 Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJwM{[yPFQh|ryP NYLF[2k6W0GQR1XS
LB771-HNC MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG5TWM2OD1{LkW3OVUyKM7:TR?= MXzTRW5ITVJ?
NCCIT MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj5S3RKSzVyPUKuPFY3OTZizszN M{XTUnNCVkeHUh?=
NCI-H2126 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTXTWM2OD1{Lki3OVUzKM7:TR?= NVv1ZYJLW0GQR1XS
Calu-6 NGfvTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTNwMEW3OFEh|ryP NXnvXXlkW0GQR1XS
SK-LMS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfMdnNpUUN3ME2zMlEyQDh4IN88US=> MUPTRW5ITVJ?
ARH-77 MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILDOZpKSzVyPUOuOFY6OTVizszN MXvTRW5ITVJ?
NB17 NWjxXHR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHUTWM2OD1|Lk[zPFQ4KM7:TR?= MoXEV2FPT0WU
A253 NEe4SnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1WyVmlEPTB;Mz63N|I1PiEQvF2= NFz4O5lUSU6JRWK=
OPM-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTRwMke2PFUh|ryP M2j3[nNCVkeHUh?=
MV-4-11 M{DnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fyPWlEPTB;ND6zOlQ2PCEQvF2= MU\TRW5ITVJ?
SR M1TQUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnZTWM2OD12LkS5PVU1KM7:TR?= NGjIZmZUSU6JRWK=
KG-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoryTWM2OD12Lk[wPFQ2KM7:TR?= MWDTRW5ITVJ?
OCI-AML2 MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zJeWlEPTB;NT64OlE2PCEQvF2= NYTTfWVPW0GQR1XS
D-247MG MmPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3PeopKSzVyPU[uNVI2OTlizszN MljZV2FPT0WU
DJM-1 M{HxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4KwfWlEPTB;Nj60PFU2QCEQvF2= NFvDUWxUSU6JRWK=
RPMI-6666 M1:1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTdwMkewOlch|ryP MWjTRW5ITVJ?
KARPAS-45 NFPw[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn2TWM2OD15LkWxOlcyKM7:TR?= NFrXSVJUSU6JRWK=
LP-1 NYDhU3FuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzITIRKSzVyPUeuOVQ4QDJizszN Mm\5V2FPT0WU
RS4-11 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\ZRWlEPTB;Nz62OVc5PyEQvF2= MoXnV2FPT0WU
DU-4475 Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRThwMkG2OVIh|ryP Mkf0V2FPT0WU
MONO-MAC-6 NYr0b2lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfOSZBKSzVyPUiuNlcxPjZizszN NH;lcpBUSU6JRWK=
NCI-SNU-16 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDL[JZKSzVyPUiuOVYyOjhizszN NHryZY9USU6JRWK=
SJSA-1 NYDmXnlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT6fnRkUUN3ME24MlczQDB3IN88US=> M1fCcnNCVkeHUh?=
MMAC-SF NX;TS4VjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXVTWM2OD16Lke5N|A4KM7:TR?= NV\W[4lUW0GQR1XS
SK-NEP-1 NYTnW21pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Li[WlEPTB;OD64PVE2PSEQvF2= NHPpSGdUSU6JRWK=
J-RT3-T3-5 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MluyTWM2OD16Lkm2OVI6KM7:TR?= NGrkTFVUSU6JRWK=
SKM-1 M4\KNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X1TGlEPTB;OT6wNVc{PCEQvF2= NV36[YhOW0GQR1XS
LB2241-RCC M1PqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTlwMEKwNVIh|ryP NFzIOllUSU6JRWK=
SIG-M5 NFfsUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTlwMEK0PVMh|ryP NUnRblJjW0GQR1XS
EVSA-T MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DPTWlEPTB;OT6yO|c6OyEQvF2= MV;TRW5ITVJ?
GT3TKB NYf6W4VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTlwM{W1OFYh|ryP NVjGeXJ6W0GQR1XS
NB6 NEnhfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTlwOUKyOVkh|ryP NW\JRZhnW0GQR1XS
EHEB Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XtN2lEPTB;MUCuNFY2PiEQvF2= MVrTRW5ITVJ?
HEL MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;j[Ih[UUN3ME2xNE41Pzd4IN88US=> MYfTRW5ITVJ?
ALL-PO MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HidWlEPTB;MUCuO|k{QCEQvF2= NVHwOmN[W0GQR1XS
TGW NX;FXWlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q3VWlEPTB;MUGuNlgzQCEQvF2= Mkn4V2FPT0WU
BC-3 NHnsfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHn5XppKSzVyPUGyMlEyOzhizszN MkTTV2FPT0WU
IA-LM NEeyNGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTtTWM2OD1zMj60OFQ2KM7:TR?= M1vXenNCVkeHUh?=
UACC-257 NHW1O5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF{LkmxPVgh|ryP MXLTRW5ITVJ?
KP-N-YS NUTZfXU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF{LkmyPFMh|ryP NHniWIFUSU6JRWK=
Raji MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF|Lke0PVch|ryP NWLoTmtRW0GQR1XS
SF539 M1P6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDwTWM2OD1zMz64OVU4KM7:TR?= MWDTRW5ITVJ?
DMS-153 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TCdGlEPTB;MUSuNFAzQCEQvF2= M4LpT3NCVkeHUh?=
L-540 M4\xNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkC1TWM2OD1zNT6wOlczKM7:TR?= MkPvV2FPT0WU
MN-60 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\zfXhSUUN3ME2xOU4yQTd7IN88US=> M17TWnNCVkeHUh?=
RPMI-8866 M1:zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL6blR1UUN3ME2xO{41PDV2IN88US=> NXH1[YdpW0GQR1XS
NCI-H510A NIT3eIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr1TWM2OD1zOT6zPVc{KM7:TR?= NWC2bY0{W0GQR1XS
NB13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PBOWlEPTB;MUmuOFg4PyEQvF2= NX7JUppyW0GQR1XS
HAL-01 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL6NZJXUUN3ME2xPU44PTR|IN88US=> MUfTRW5ITVJ?
NCI-H720 M4rwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnEfGFPUUN3ME2yNE4zPzN|IN88US=> MV;TRW5ITVJ?
REH NXfZcoxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPwPIpKSzVyPUKwMlY{PTdizszN M{fJbXNCVkeHUh?=
KNS-81-FD M3:1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnuTWM2OD1{Mz6xOFYh|ryP MULTRW5ITVJ?
HC-1 M{nvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ2LkW1OVEh|ryP NHHHTlRUSU6JRWK=
NCI-H2141 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojETWM2OD1{ND63O|U1KM7:TR?= MonkV2FPT0WU
MOLT-4 MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\R[Yk4UUN3ME2yOk43PzV|IN88US=> MoHQV2FPT0WU
OMC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFn2TWhKSzVyPUK3MlE1OjJizszN MkjRV2FPT0WU
LC-1F NV\ZNo56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrhbFVxUUN3ME2yO{4{OjR3IN88US=> NXTSeYtVW0GQR1XS
NCI-H1304 M1PMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjpfm5sUUN3ME2yPE4yPjJ6IN88US=> NYLKPIZXW0GQR1XS
BC-1 M4nMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ6Lk[1NUDPxE1? NGfGcGRUSU6JRWK=
NCI-H64 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7Tc45KSzVyPUK5MlYzPTNizszN MmDnV2FPT0WU
MOLT-16 NF75WGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmToTWM2OD1{OT62NlkzKM7:TR?= NVO4V|lsW0GQR1XS
U-87-MG NWX2eHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fFSmlEPTB;M{CuO|Y3KM7:TR?= NVHJZ|hiW0GQR1XS
GAK NVz6SZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTNzLkK2PFYh|ryP Ml2zV2FPT0WU
ES8 NXnhRpk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN{LkGyOVIh|ryP MXnTRW5ITVJ?
HCC1599 NILnTFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\FdHpKSzVyPUOyMlM{OjVizszN M2rCTHNCVkeHUh?=
EB-3 M2X2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX5TWM2OD1|ND6zNVE4KM7:TR?= NWDRe3RXW0GQR1XS
HCC1187 NHi5SG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLjVldxUUN3ME2zOU45ODV{IN88US=> MWHTRW5ITVJ?
SK-PN-DW NH7pNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTN4LkG5OFMh|ryP MY\TRW5ITVJ?
JVM-3 NEezUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTN5LkKzN|gh|ryP M1zTeHNCVkeHUh?=
HCC2157 M33hZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrGVoMxUUN3ME2zO{46QTR4IN88US=> MVLTRW5ITVJ?
A4-Fuk MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTN6LkGwNFkh|ryP NX[zZlBvW0GQR1XS
COR-L279 MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:3VWU6UUN3ME20NE4zQDVzIN88US=> MWHTRW5ITVJ?
DEL NIfjbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjU[ZRpUUN3ME20NU46ODh4IN88US=> MW\TRW5ITVJ?
NCI-H1395 M4f4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfUTWM2OD12Mj6wNVY{KM7:TR?= M3P6eXNCVkeHUh?=
MHH-NB-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTR|LkC4NVgh|ryP NWi1TI92W0GQR1XS
NCI-H2107 NVXz[odVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLpTWM2OD12Mz60PFQ3KM7:TR?= NWfwZYlDW0GQR1XS
NEC8 NFjzT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTR2LkOzOkDPxE1? M{X1UHNCVkeHUh?=
COLO-684 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlOzTWM2OD12Nj6yNlU5KM7:TR?= M4jLd3NCVkeHUh?=
LS-411N MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrweod[UUN3ME20PE41PzR6IN88US=> MkPRV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Related Antibodies

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID